Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q2 2024 call → NOWe need to determine if management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is already visible. The key elements: (1) a proven instance that works, (2) copies being stood up now, (3) demand already identified at destination. Also, replication large relative to company. Let's examine the transcript. The company is Mesoblast, developing cell therapies. They have products like remestemcel (RYONCIL) for GVHD, rexlemestrocel for heart failure and back pain. They have clinical trials, regulatory interactions. The question asks about "copying a part of its own business" - i.e., replicating a proven unit. In this context, it might refer to expanding into new indications or markets? But the phrasing "additional places where the same demand is already visible" suggests geographic expansion, new sites, etc. However, the company is a biotech with manufacturing and clinical trials. They have a manufacturing process that is scalable. They mention "commercial scale manufacturing process that is highly scalable" and "off-the-shelf" product. But they are not currently standing up new manufacturing facilities? They have a facility in Singapore that was inspected. They talk about "3D bioreactors for high volume indications" as future innovations. The call is about financial results and operational update. They discuss progress on clinical trials, regulatory meetings. They mention starting a Phase 3 trial for adult GVHD, and a pivotal trial for back pain that has commenced. But these are clinical trials, not proven business units. The company has not yet received approval for any product in the US. They have royalties from TEMCELL in Japan. So the "proven instance" might be the product that works? But they are still in development. The question specifically asks: "does management describe the company as CURRENTLY IN THE MIDDLE OF COPYING A PART OF ITS OWN BUSINESS THAT IS ALREADY WORKING INTO ADDITIONAL PLACES WHERE THE SAME DEMAND IS ALREADY VISIBLE" - This seems to be about replication of a proven business model, like opening new stores, new clinics, etc. In biotech, it might be expanding into new indications? But that's not exactly "copying" a proven unit. The company is developing multiple products for different indications. They have a platform technology.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.